Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Shilpa Medicare Ltd    SHILPAMED   INE790G01031

SHILPA MEDICARE LTD

(SHILPAMED)
  Report  
End-of-day quote. End-of-day quote NATIONAL STOCK EXCHANGE OF INDIA - 09/18
245.1 INR   -3.48%
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

Shilpa Medicare : gets USFDA nod for cancer treatment injection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/02/2019 | 03:30am EDT

Shilpa Medicare Tuesday said it has received approval from the US health regulator for Irinotecan HCL injection, used for treatment of certain kind of cancers.

The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.

Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added.

Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Irinotecan HCL is approximately USD 18 million.

Shares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on BSE.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHILPA MEDICARE LTD
01/02SHILPA MEDICARE : gets USFDA nod for cancer treatment injection
AQ
2018SHILPA MEDICARE : gets tentative USFDA nod for multiple sclerosis drug
AQ
2018SHILPA MEDICARE : Armas and Shilpa Enter into a Sales and Distribution Agreement..
AQ
2018SHILPA MEDICARE : Trailing twelve month results - shilpa medicare limited
AQ
2018SHILPA MEDICARE : Quarterly results - shilpa medicare limited
AQ
More news
Financials (INR)
Sales 2020 7 802 M
EBIT 2020 1 326 M
Net income 2020 1 191 M
Debt 2020 -
Yield 2020 0,29%
P/E ratio 2020 16,8x
P/E ratio 2021 12,5x
Capi. / Sales2020 2,56x
Capi. / Sales2021 2,08x
Capitalization 20 007 M
Chart SHILPA MEDICARE LTD
Duration : Period :
Shilpa Medicare Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHILPA MEDICARE LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 346,00  INR
Last Close Price 245,10  INR
Spread / Highest target 67,3%
Spread / Average Target 41,2%
Spread / Lowest Target 15,1%
EPS Revisions
Managers
NameTitle
Vishnukanth Bhutada Chaturbhuj Managing Director & Executive Director
Omprakash Tulsiram Inani Chairman
Sushil Bajaj Chief Financial Officer
Prashant Purohit Vice President-Research & Development
Sharath Reddy Vice President-Technical
Sector and Competitors
1st jan.Capitalization (M$)
SHILPA MEDICARE LTD-34.13%290
JOHNSON & JOHNSON0.38%342 221
ROCHE HOLDING LTD.14.65%240 139
MERCK AND COMPANY7.98%211 257
PFIZER-16.38%201 883
NOVARTIS15.63%198 222